SOLID FORMS OF AN ANTIVIRAL COMPOUND

摘要

Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5 -(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro [2 .4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state:;;Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.

主权项

1. Crystalline (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I Form III) characterized by an X-ray powder diffractogram comprising the following peaks: 12.4, 14.2, and 21.6°2θ±0.2 °2θ, as determined on a diffractometer using Cu—Kα radiation at a wavelength of 1.54178 Å.